Richards Angelene F, Baranova Danielle E, Pizzuto Matteo S, Jaconi Stefano, Willsey Graham G, Torres-Velez Fernando J, Doering Jennifer E, Benigni Fabio, Corti Davide, Mantis Nicholas J
Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York 12208, United States.
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York 12208, United States.
ACS Infect Dis. 2021 May 14;7(5):1221-1235. doi: 10.1021/acsinfecdis.0c00842. Epub 2021 Mar 17.
As the predominant antibody type in mucosal secretions, human colostrum, and breast milk, secretory IgA (SIgA) plays a central role in safeguarding the intestinal epithelium of newborns from invasive enteric pathogens like the Gram-negative bacterium serovar Typhimurium (STm). SIgA is a complex molecule, consisting of an assemblage of two or more IgA monomers, joining (J)-chain, and secretory component (SC), whose exact functions in neutralizing pathogens are only beginning to be elucidated. In this study, we produced and characterized a recombinant human SIgA variant of Sal4, a well-characterized monoclonal antibody (mAb) specific for the O5-antigen of STm lipopolysaccharide (LPS). We demonstrate by flow cytometry, light microscopy, and fluorescence microscopy that Sal4 SIgA promotes the formation of large, densely packed bacterial aggregates . In a mouse model, passive oral administration of Sal4 SIgA was sufficient to entrap STm within the intestinal lumen and reduce bacterial invasion into gut-associated lymphoid tissues by several orders of magnitude. Bacterial aggregates induced by Sal4 SIgA treatment in the intestinal lumen were recalcitrant to immunohistochemical staining, suggesting the bacteria were encased in a protective capsule. Indeed, a crystal violet staining assay demonstrated that STm secretes an extracellular matrix enriched in cellulose following even short exposures to Sal4 SIgA. Collectively, these results demonstrate that recombinant human SIgA recapitulates key biological activities associated with mucosal immunity and raises the prospect of oral passive immunization to combat enteric diseases.
作为黏膜分泌物、人初乳和母乳中的主要抗体类型,分泌型免疫球蛋白A(SIgA)在保护新生儿肠道上皮免受侵袭性肠道病原体(如革兰氏阴性菌鼠伤寒血清型(STm))侵害方面发挥着核心作用。SIgA是一种复杂分子,由两个或更多免疫球蛋白A单体、连接(J)链和分泌成分(SC)组成,其在中和病原体方面的确切功能才刚刚开始得到阐明。在本研究中,我们制备并表征了Sal4重组人SIgA变体,Sal4是一种针对STm脂多糖(LPS)O5抗原的特征明确的单克隆抗体(mAb)。我们通过流式细胞术、光学显微镜和荧光显微镜证明,Sal4 SIgA促进形成大的、紧密堆积的细菌聚集体。在小鼠模型中,被动口服Sal4 SIgA足以将STm截留在肠腔内,并将细菌侵入肠道相关淋巴组织的数量减少几个数量级。Sal4 SIgA处理在肠腔内诱导的细菌聚集体对免疫组织化学染色具有抗性,表明细菌被包裹在一个保护性荚膜中。事实上,结晶紫染色试验表明,即使短时间暴露于Sal4 SIgA后,STm也会分泌富含纤维素的细胞外基质。总体而言,这些结果表明重组人SIgA概括了与黏膜免疫相关的关键生物学活性,并提高了口服被动免疫对抗肠道疾病的前景。